• Deciphera Pharmaceuticals Wins Early FDA Nod for GI Cancer Treatment

    10 days ago - By Xconomy

    Some patients with a deadly type of tumor that forms in the gastrointestinal tract don't respond to existing targeted therapies. On Friday the FDA approved Deciphera Pharmaceuticals drug ripretinib , a new treatment intended for patients with a gastrointestinal stromal tumor who have failed at least three previous treatments. Deciphera said the agency's approval, the company's first, arrived three months earlier than expected. The Waltham, MA-based biotech announced plans to seek FDA approval of the cancer medicine last August. That application was accepted in February under priority...
    Read more ...